Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England.

Tendai Mugwagwa Ahuva AverinMark AtwoodReiko Sato Andrew Vyse James Campling Derek Weycker Mary P E Slack Gillian F Ellsbury Diana Mendes

Published in: Expert review of vaccines (2022)

Use of PCV20 among adults currently eligible for PPV23 in England would substantially reduce the burden of pneumococcal disease, with modest budgetary impact.

Keyphrases

public health
cancer therapy
drug delivery